New 1H,3H-oxazolo[3,4-a]benzimidazoles (OBZs) were synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTI) to extend the structure-activity relationships observed for an early series of related 1H,3H-thiazolo[3,4-a]benzimidazole derivatives (TBZs). The new compounds showed inhibitory activity against the replication of various HIV-1 strains, including NNRTI-resistant strains. Testing of a representative OBZ derivative in an HPLC assay on biological fluids, indicated that the sulphur substitution appreciably improved the metabolic stability of the TBZ compound. In addition, molecular modelling studies demonstrated that OBZs, TBZs and other NNRTIs have similar structural properties, that is a butterfly-like conformation, which is a key structural requirement for reverse transcriptase inhibition.
BalzariniJKarlssonAPérez-PérezMJVrangLWalbergJZhangHObergBVandammeAMBathurstICBarrPJCamarasaMJ & De ClercqE (1993) HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitution in the reverse transcriptase. Virology192: 246–253.
2.
BarrecaMLChimirriACarottiACarrieriAMonforteAMCalacePellegrini M & RaoA (1999) Comparative Molecular Field Analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNRTIs). Bioorganic and Medicinal Chemistry7: 2283–2292.
3.
BuckheitRWHollingsheadMGGermany-DeckerJWhiteELMcMahonJBAllenLBRossLJDeckerWDWestbrookLShannonWMWeislowOBaderJP & BoydMR (1993) Thiazolobenzimidazole: Biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Research21: 247–265.
4.
ChimirriAGrassoSMonforteAMMonforteP & ZappalàM (1991a) Anti-HIV agents I. Synthesis and anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. II Farmaco46: 817–823.
5.
ChimirriAGrassoSMonforteAMMonforteP & ZappalàM (1991b) Anti-HIV agents II. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. II Farmaco46: 925–933.
6.
ChimirriAGrassoSMonforteAMMonforteP & ZappalàM (1994) Anti-HIV agents III. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]imidazo[4,5-b]pyridines. II Farmaco49: 345–348.
7.
ChimirriAGrassoSMolicaCMonforteAMMonfortePZappalàM & ScopellitiR (1996) Anti-HIV agents IV. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)- 1H,3H-thiazolo[3,4-a]benzimidazoles. II Farmaco51: 279–282.
8.
ChimirriAGrassoSMolicaCMonforteAMMonfortePZappalàMBrunoGNicolóFWitvrouwMJonckeereHBalzariniJ & De ClercqE (1997a) Structural features and antihuman immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chemistry & Chemotherapy8: 363–370.
9.
ChimirriAGrassoSMonforteAMMonfortePRaoA.ZappalàMBrunoGNicolóF & ScopellitiR (1997b) Anti-HIV agents V. Synthesis, structure and in vitro anti-HIV activity of novel 1H,3H-naphtho[2′,3′:4,5]imidazo[1,2-c]thiazoles. II Farmaco52: 673–677.
10.
ChimirriAGrassoSMonforteAMMonfortePRaoA.ZappalàMBrunoGNicolóFPannecouqueC.WitvrouwM & De ClercqE (1998) Synthesis, structure and in vitro antihuman immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazole. Antiviral Chemistry & Chemotherapy9: 431–438.
11.
ChimirriAGrassoSMonfortePRaoA.ZappalàMMonforteAMPannecouqueCWitvrouwMBalzariniJ & De ClercqE (1999) Synthesis and biological activity of novel 1h,3h-thiazolo[3,4-a]benzimidazoles: Non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antiviral Chemistry & Chemotherapy10: 211–217.
12.
ClarkMCramerRDIII & Van OpdemboshN (1989) Validation of the general purpose Tripos 5.2 force field. Journal of Computational Chemistry10: 982–1012.
13.
De ClercqE (1996) Non-nucleoside reverse transcriptase inhibitors (nnrtis) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development. Medicinal Research Review16: 125–157.
14.
De ClercqE (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Research38: 153–179.
15.
De ClercqEPlattnerJJ & ChuDT (1999) An introduction to current opinion in anti-infective investigational drugs. Current Opinion in Antiinfective Investigational Drugs1: 1–3.
16.
DingJDasKMoereelsHKoymansLAndriesKJanssenPAJHuglesSH & ArnoldE (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Structural Biology2: 407–415.
17.
El DareerSMTilleryKFRoseLMPoseyCFStruckRFStillerSW & HillDL (1993) Metabolism and disposition of a thiazolobenzimidazole active against human immunodeficiency virus- 1. Drug Metabolism and Disposition21: 231–235.
18.
HajosGRiediSMolnarJ & SzaboD (2000) Nonnucleoside reverse transcriptase inhibitors. Drugs of the Future25: 47–62.
19.
PauwelsRBalzariniJBabaMSnoeckRScholsDHerdewijinPDesmyterJ & De ClercqE (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods20: 309–321.
SchultzRJBaderJPChimirriACoveyJMHillDLHaugwitzRDGuziecFS & NarayananVL (1992) Thiazolobenzimidazoles-a new class of anti-HIV agents. Proceedings of the American Association for Cancer Research33: 517.
22.
WitvrouwMScholsDAndreiGSnoeckRHosoyaMPauwelsRBalzariniJ & De ClercqE (1991) Antiviral activity of low-MW dextran sulfate (derived from dextran MW 1000) compared to dextran sulfate samples of higher MW. Antiviral Chemistry & Chemotherapy2: 171–179.
